{
    "root": "db2757aa-d8c7-4114-b4bb-5eeec0df762f",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Arsenic trioxide",
    "value": "20250512",
    "ingredients": [
        {
            "name": "ARSENIC TRIOXIDE",
            "code": "S7V92P67HO",
            "drugbank_id": "https://go.drugbank.com/drugs/DB01169"
        },
        {
            "name": "SODIUM HYDROXIDE",
            "code": "55X04QC32I",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32145"
        },
        {
            "name": "HYDROCHLORIC ACID",
            "code": "QTT17582CB",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_37527"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_15377"
        }
    ],
    "indications": {
        "text": "arsenic trioxide injection arsenical indicated : combination tretinoin treatment adults newly-diagnosed low-risk acute promyelocytic leukemia ( apl ) whose apl characterized presence ( 15 ; 17 ) translocation pml/rar-alpha gene expression . ( 1.1 ) induction remission consolidation patients apl refractory , relapsed , retinoid anthracycline chemotherapy , whose apl characterized presence ( 15 ; 17 ) translocation pml/rar-alpha gene expression . ( 1.2 )",
        "doid_entities": [
            {
                "text": "acute promyelocytic leukemia (DOID:0060318)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_0060318"
            },
            {
                "text": "leukemia (DOID:1240)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1240"
            }
        ],
        "orphanet_entities": [
            {
                "disease": "acute promyelocytic leukemia",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_520"
            }
        ]
    },
    "contraindications": {
        "text": "newly-diagnosed low-risk apl : induction : administer 0.15 mg/kg/day intravenously daily combination tretinoin bone marrow remission . exceed 60 days . ( 2.1 ) consolidation : administer 0.15 mg/kg/day intravenously daily 5 days per week weeks 1-4 8-week cycle total 4 cycles combination tretinoin . ( 2.1 ) relapsed refractory apl : induction : administer 0.15 mg/kg/day intravenously daily bone marrow remission . exceed 60 days . ( 2.2 ) consolidation : administer 0.15 mg/kg/day intravenously daily 25 doses period 5 weeks . ( 2.2 )",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "supplied arsenic trioxide injection supplied sterile , clear , colorless solution 10 ml glass , single-dose vials . ndc strength pack style 70710-1895-6 10 mg per 10 ml single-dose vials 10 vials per carton storage handling store 20\u00b0c 25\u00b0c ( 68\u00b0f 77\u00b0f ) ; excursions permitted 15\u00b0c 30\u00b0c ( 59\u00b0f 86\u00b0f ) [ usp controlled room temperature ] . freeze . arsenic trioxide hazardous . follow applicable special handling disposal procedures.1",
    "adverseReactions": "arsenic trioxide contraindicated patients hypersensitivity arsenic .",
    "indications_original": "Arsenic trioxide injection is an arsenical indicated: In combination with tretinoin for treatment of adults with newly-diagnosed low-risk acute promyelocytic leukemia (APL) whose APL is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression. ( 1.1 ) For induction of remission and consolidation in patients with APL who are refractory to, or have relapsed from, retinoid and anthracycline chemotherapy, and whose APL is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression. ( 1.2 )",
    "contraindications_original": "Newly-diagnosed low-risk APL: Induction: Administer 0.15 mg/kg/day intravenously daily in combination with tretinoin until bone marrow remission. Do not exceed 60 days. ( 2.1 ) Consolidation: Administer 0.15 mg/kg/day intravenously daily for 5 days per week during weeks 1-4 of each 8-week cycle for a total of 4 cycles in combination with tretinoin. ( 2.1 ) Relapsed or refractory APL: Induction: Administer 0.15 mg/kg/day intravenously daily until bone marrow remission. Do not exceed 60 days. ( 2.2 ) Consolidation: Administer 0.15 mg/kg/day intravenously daily for 25 doses over a period of up to 5 weeks. ( 2.2 )",
    "warningsAndPrecautions_original": "How Supplied\n                  \n                  Arsenic trioxide injection is supplied as a sterile, clear, colorless solution in 10 mL glass, single-dose vials.\n                  \n                     \n                     \n                     \n                     \n                        \n                           \n                               NDC\n                              \n                           \n                           \n                               Strength\n                              \n                           \n                           \n                               Pack Style\n                              \n                           \n                        \n                        \n                            70710-1895-6\n                           \n                            10 mg per 10 mL single-dose vials\n                           \n                            10 vials per carton\n                           \n                        \n                     \n                  \n                  \n                     Storage and Handling\n                  \n                  Store at 20\u00b0C to 25\u00b0C (68\u00b0F to 77\u00b0F); excursions permitted to 15\u00b0C to 30\u00b0C (59\u00b0F to 86\u00b0F) [See USP Controlled Room Temperature]. Do not freeze.\n                  Arsenic trioxide is a hazardous drug. Follow applicable special handling and disposal procedures.1",
    "adverseReactions_original": "Arsenic trioxide is contraindicated in patients with hypersensitivity to arsenic.",
    "drug": [
        {
            "name": "Arsenic trioxide",
            "drugbank_id": "https://go.drugbank.com/drugs/DB01169"
        }
    ]
}